NYSTATIN AND TRIAMCINOLONE ACETONIDE- nystatin and triamcinolone acetonide cream NuCare Pharmaceuticals,Inc.

Nystatin and Triamcinolone Acetonide Cream, USP

Nystatin and Triamcinolone Acetonide Ointment, USP


Rx only

FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE.


DESCRIPTION

Nystatin and Triamcinolone Acetonide Cream and Ointment for dermatologic use contain the antifungal agent nystatin and the synthetic corticosteroid triamcinolone acetonide.

Nystatin is a polyene antimycotic obtained from Streptomyces noursei. It is a yellow to light tan powder with a cereallike odor, very slightly soluble in water, and slightly to sparingly soluble in alcohol. Structural formula:



Triamcinolone acetonide is designated chemically as 9-fluoro-11 β , 16 α , 17, 21tetrahydroxypregna-1, 4-diene-3, 20-dione cyclic 16, 17-acetal with acetone. The white to cream crystalline powder has a slight odor, is practically insoluble in water, and very soluble in alcohol. Structural formula:



 $C_{24}H_{31}FO_{6}MW = 434.50$

Nystatin and Triamcinolone Acetonide Cream is a soft, smooth cream having a light yellow to buff color. Each gram provides 100,000 USP Nystatin units and 1 mg Triamcinolone Acetonide in an aqueous perfumed vanishing cream base with polysorbate-60, aluminum hydroxide, titanium dioxide, glyceryl monostearate, polyethylene glycol monostearate, simethicone emulsion, sorbic acid, propylene glycol, white petrolatum, polyoxyethylene fatty alcohol ether, methylparaben, propylparaben and sorbitol.

Each gram of Nystatin and Triamcinolone Acetonide Ointment provides 100,000 USP Nystatin units and 1 mg Triamcinolone Acetonide in an ointment base of mineral oil and white petrolatum.

CLINICAL PHARMACOLOGY

Nystatin

Nystatin exerts its antifungal activity against a variety of pathogenic and nonpathogenic yeasts and fungi by binding to sterols in the cell membrane. The binding process renders the cell membrane incapable of functioning as a selective barrier. Nystatin provides specific anticandidal activity to *Candida* (Monilia) *albicans* and other Candida species, but is not active against bacteria, protozoa, trichomonads, or viruses.

Nystatin is not absorbed from intact skin or mucous membranes.

Triamcinolone Acetonide

Triamcinolone acetonide is primarily effective because of its anti-inflammatory, antipruritic and vasoconstrictive actions, characteristic of the topical corticosteroid class of drugs. The pharmacologic effects of the topical corticosteroids are well known; however, the mechanisms of their dermatologic actions are unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.

Pharmacokinetics

the extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings (see **DOSAGE AND ADMINISTRATION**).

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids (see **DOSAGE AND ADMINISTRATION**).

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

Nystatin and Triamcinolone Acetonide

During clinical studies of mild to severe manifestations of cutaneous candidiasis, patients treated with nystatin and triamcinolone acetonide showed a faster and more pronounced clearing of erythema and pruritus than patients treated with nystatin or triamcinolone acetonide alone.

INDICATIONS AND USAGE

Nystatin and Triamcinolone Acetonide Cream and Ointment are indicated for the treatment of cutaneous candidiasis; it has been demonstrated that the nystatin-steroid combination provides greater benefit than the nystatin component alone during the first few days of treatment.

CONTRAINDICATIONS

These preparations are contraindicated in those patients with a history of hypersensitivity to any of their components.

PRECAUTIONS

General

Systemic absorption of topical corticosteroids has produced reversible hypothalamicpituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. Conditions that augment systemic absorption include application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings (see **DOSAGE AND ADMINISTRATION**).

Therefore, patients receiving a large dose of any potent topical steroid applied to a large surface area should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests, and for impairment of internal homeostasis. If HPA axis suppression or elevation of the body temperature occurs, an attempt should be made to withdraw the drug, to reduce the frequency of application, or substitute a less potent steroid. Recovery of HPA axis function and thermal homeostasis are generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.

Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see **PRECAUTIONS, Pediatric Use**).

If irritation or hypersensitivity develops with the combination nystatin and triamcinolone acetonide, treatment should be discontinued and appropriate therapy instituted.

Information for the Patient

Patients using this medication should receive the following information and instructions:

- 1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
- 2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed.
- 3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occluded (see **DOSAGE AND ADMINISTRATION**).
- 4. Patients should report any signs of local adverse reactions.
- 5. When using this medication in the inguinal area, patients should be advised to apply the cream or ointment sparingly and to wear loose fitting clothing.
- 6. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.
- 7. Patients should be advised on preventive measures to avoid reinfection.

Laboratory Tests

If there is a lack of therapeutic response, appropriate microbiological studies (e.g. KOH smears and/or cultures) should be repeated to confirm the diagnosis and rule out other pathogens, before instituting another course of therapy.

A urinary free cortisol test and ACTH stimulation test may be helpful in evaluating hypothalamic-pituitary-adrenal (HPA) axis suppression due to corticosteroids.

Carcinogenesis, Mutagenesis, and Impairment of Fertility

Long-term animal studies have not been performed to evaluate carcinogenic or mutagenic potential, or possible impairment of fertility in males or females.

Pregnancy Category C

There are no teratogenic studies with combined nystatin and triamcinolone acetonide. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Therefore, any topical corticosteroid preparation should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Topical preparations containing corticosteroids should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

Nursing Mothers

It is not known whether any component of this preparation is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised during the use of this preparation by a nursing woman.

Pediatric Use

In clinical studies of a limited number of pediatric patients ranging from two months through 12 years, nystatin and triamcinolone acetonide cream formulation cleared or significantly ameliorated the disease state in most patients.

Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hypothalamic-pituitary-adrenal (HPA) axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.

HPA axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.

ADVERSE REACTIONS

A single case (approximately one percent of patients studied) of acneiform eruption occurred with use of combined nystatin and triamcinolone acetonide in clinical studies.

Nystatin is virtually nontoxic and nonsensitizing and is well tolerated by all age groups, even during prolonged use. Rarely, irritation may occur.

The following local adverse reactions are reported infrequently with topical corticosteroids (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, perioral secondary infection, skin atrophy, striae and miliaria.

OVERDOSAGE

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see **PRECAUTIONS, General**); however, acute overdosage and serious adverse effects with dermatologic use are unlikely.

DOSAGE AND ADMINISTRATION

Nystatin and Triamcinolone Acetonide Cream is usually applied to the affected areas twice daily in the morning and evening by gently and thoroughly massaging the

preparation into the skin. The cream should be discontinued if symptoms persist after 25 days of therapy (see **PRECAUTIONS, Laboratory Tests**).

A thin film of Nystatin and Triamcinolone Acetonide Ointment is usually applied to the affected areas twice daily in the morning and evening. The preparation should be discontinued if symptoms persist after 25 days of therapy (see **PRECAUTIONS, Laboratory Tests**).

Nystatin and Triamcinolone Acetonide Cream and Ointment should not be used with occlusive dressings.

HOW SUPPLIED

Nystatin and Triamcinolone Acetonide Cream is supplied in 30 g.

NDC 68071-5037-3 BOX OF 30g

STORAGE

Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. Avoid freezing.

Mfd. by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada L6T 1C1

Revised: September, 2004

PK-1111-2 141

PRINCIPAL DISPLAY PANEL -

| O NuC | NuCare Pharmaceuticals, Inc. | | | | | |
|---|---|---|--|--|--|--|
| | ■ A PORTAGE AND A CONTRACT AND A CO | | | | | |
| A 92867 SA 92867 SA 92867 SA 92867 SA 92867 SA 92867 SA 92867 SA 92867 SA 92867 | Cream | Nystatin/Triamcinolone Acetonide Lot: 000000 NDC: 68071-5037-03 MFR NDC: 51672-1263-2 Exp.: 00-00 Serial# 00000000002 | | | | |
| | anufacturer's label list of ingredients | GTIN 00368071503739 Serial# 0000000002 Exp. Date 00-00 LOT#: 000000 | | | | |
| Rev 01/01/19 | Product #: R0312030 | Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. ONTROLLED TEMPERATURE 68-77°F. | | | | |

NYSTATIN AND TRIAMCINOLONE ACETONIDE

nystatin and triamcinolone acetonide cream

Product Information

| NYSTATIN (UNII: BDF101C72E) (NYSTATIN - UNII:BDF101C72E) NYSTATIN 100000 [USP(L in 1 g) TRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE - UNII:F446C597KA) TRIAMCINOLONE ACETONIDE - UNII:F446C597KA) TRIAMCINOLONE ACETONIDE - UNII:F446C597KA) TRIAMCINOLONE TRIAMCINOLONE ACETONIDE - UNII:F446C597KA) Triamcinolone TRIAMCINOLONE TRIAMCINOLONE ACETONIDE - UNII:F446C597KA) Triamcinolone TRIAMCINOLONE TRIAMCINO | | | | | | | | |
|---|--------------------------|-----------------|-----------------------------|---------|------------|-----------|--------------------------|--|
| Active Ingredient/Active Moiety Ingredient Name Basis of Strength NYSTATIN (UNII: BOFLOIC72E) NYSTATIN III 00000 (USPU III) 1 TRIAMCINOLONE ACETONIDE (UNII: F446CS97KA) (TRIAMCINOLONE ACETONIDE ACETONIDE - UNII:F446CS97KA) (TRIAMCINOLONE ACETONIDE IIII) 1 TRIAMCINOLONE ACETONIDE (UNII: F446CS97KA) (TRIAMCINOLONE ACETONIDE IIII) 1 IIII 1 IIIII 1 IIII 1 IIII 1 IIII 1 IIIII 1 IIII 1 IIIII 1 IIIIII 1 IIIII 1 IIIIII 1 IIIIII 1 IIIIIIIIII | Product Type | | | | | | 71-5037(NDC:51672- | |
| Ingredient Name Basis of Strength Strength NYSTATIN (UNII: BDF101C72E) (NYSTATIN - UNII:BDF101C72E) NYSTATIN 100000 [USP(L in 1 g) TRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE - UNII:F446C597KA) (TRIAMCINOLONE ACETONIDE - UNII:F446C597KA) (TRIAMCINOLONE ACETONIDE - UNII: F446C597KA) 1 mg in 1 g Inactive Ingredients Ingredient Name POLYSORBATE 60 (UNII: CAL22U1/M4M) ALUMINUM HYDROXIDE (UNII: S08009XE4) SORBIC ACID (UNII: S045W9898) PEROPYLENE GLYCOL (UNII: 5060921UN0) TTTAILUM DIOXIDE (UNII: S045W9898) PEROPYLENE GLYCOL (UNII: 506160425R) Strength PEROPYLENE GLYCOL (UNII: S08175210H) SORBITOL (UNII: 28025210H) SORBITOL (UNI | Route of Administ | tration | TOPICAL | | | | | |
| Ingredient Name Basis of Strength Strength NYSTATIN (UNII: BDF101C72E) (NYSTATIN - UNII:BDF101C72E) NYSTATIN 100000 [USP(L in 1 g) TRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE - UNII: F446C597KA) 1 mg in 1 g Inactive Ingredients Ingredient Name POLYSORBATE 60 (UNII: CAL22UV4M) ALUMINUM HYDROXIDE (UNII: S08009XE4) SORBIC ACID (UNII: F5FK922P) GLYCERVL MONOSTEARATE (UNII: 23009XE4) SORBIC ACID (UNII: K045W9898) PROPYLENE GLYCOL (UNII: 60C90167V3) PETROLATUM (UNII: 80E25C10H) SORBITOL (UNII: 5080560A25R) Score Product Characteristics Score Color yellow (light yellow to buff color) SorBITOL (UNII: S080560A25R) Size Product Characteristics Imprint Code Contains Size Packaging Marketing Start Date Marketing Information 08/21/2019 | | | | | | | | |
| Ingredient Name Strength Strength NYSTATIN (UNII: BDF101C72E) (NYSTATIN - UNII:BDF101C72E) NYSTATIN 100000 [USPL in 1 g TRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE - UNII:F446C597KA) TRIAMCINOLONE ACETONIDE - UNII:F446C597KA) 1 mg in 1 g Inactive Ingredients Ingredient Name Strength POLYSORBATE 60 (UNII: CAL22U/V4M) ACETONIDE (UNII: 508072/UN0) Img in 1 g ALUMINUM HYDROXIDE (UNII: 508072/UN0) TTTANIUM DIOXIDE (UNII: 508072/UN0) Img in 1 g STTTANUM DIOXIDE (UNII: 508072/UN0) Strength Img in 1 g GLYCERX HONOSTEARATE (UNII: 230009XXE4) Img in 1 g Img in 1 g SORBIC ACID (UNII: SORG9016773) Img in 1 g Img in 1 g PROPYLENE GLYCOL (UNII: SORG9016773) Img in 1 g Img in 1 g PROPYLENE GLYCOL (UNII: SORG022SR) Img in 1 g Img in 1 g Product Characteristics Score Imp int Code Color yellow (light yellow to buff color) Score Size Flavor Imp int Code Imp int Code Imp int Code Contains Img in 1 uBE; Type 0: Not a Combination 08/21/2019 Imp int Code Product In Code | Active Ingredie | nt/Active | Moiety | | | | | |
| NTSTAIN (0ML DPJOLC/2E) (UNI: F446C597KA) (TRIAMCINOLONE In 1 g TRIAMCINOLONE ACETONIDE (UNI: F446C597KA) (TRIAMCINOLONE TRIAMCINOLONE ACETONIDE (UNI: F446C597KA) (TRIAMCINOLONE 1 mg in 1 g Inactive Ingredients TRIAMCINOLONE ACETONIDE (UNI: F446C597KA) (TRIAMCINOLONE TRIAMCINOLONE ACETONIDE (UNI: F446C597KA) (TRIAMCINOLONE 1 mg in 1 g Inactive Ingredients Ingredient Name Strength POLYSORBATE 60 (UNI: CAL22UVIAM) Ingredient S Ingredient S Itranuou Inducting (UNI: SQB0721UN0) Ingredient S Ingredient S GLYCERYL MONOSTERATE (UNII: 2300/93XE4) Sorbit Cal (UNII: SQB0721UN0) Ingredient S SORBIC ACID (UNII: S0E00167V3) PEROLATUM (UNII: 4218C7H19T) Ingredient S PROPYLENE GLYCOL (UNII: 281X2SC10H) Sore Ingredient S SORBITOL (UNII: 2802SC10H) Score Size SORBITOL (UNII: 2802SC10H) Score Ingredient S SORBITOL (UNII: 506760A25R) Ingredient Code Ingredient S Product Characteristics Ingredient S Ingredient S Color yellow (light yellow to buff color) Score Size Flavor Ingredient S Ingredient S Ingredient S 1 Ing | | Ingree | dient Name | | | | Strength | |
| ACETONIDE - UNII:F446C597KA) ACETONIDE ACETONIDE ACETONIDE - UNII:F446C597KA) ACETONIDE (CAL22UVI4M) ALUMINUM HYDROXIDE (UNII: CAL22UVI4M) ALUMINUM HYDROXIDE (UNII: 200092XE4) SORBITAL (UNII: 200092XE4) SORE (UN | NYSTATIN (UNII: BDF: | 101C72E) (NY | STATIN - UNII:BDF101C72E |) | NYSTA | TIN | 100000 [USP'U] in 1 g | |
| Ingredient Name Strength POLYSORBATE 60 (UNII: CAL22UVI4M) ALUMINUM HYDROXIDE (UNII: SQB0T2IUN0) I I TITANIUM DIOXIDE (UNII: SGB0T2IUN0) I I SORBIC ACID (UNII: SORBATE (UNII: 2300U9XXE4) SORBIC ACID (UNII: 300U9XXE4) I SORBIC ACID (UNII: 3045W9898) I I I PROPYLENE GLYCOL (UNII: 6DC9Q167V3) PETROLATUM (UNII: 4TBH28N9U) I I METHYLPARABEN (UNII: 281X2SC10H) SORBITOL (UNII: 281X2SC10H) I I SORBITOL (UNII: SOFT60A2SR) I Size I I Product Characteristics Size Imprint Code I Imprint Code Contains I Yellow (light yellow to buff color) Size I Imprint Code Packaging # Item Code Package Description Marketing Start Marketing End 1 Sio37-3 30 g in 1 TUBE; Type 0: Not a Combination 08/21/2019 I I Marketing Information I Marketing Start Marketing End Date | | | NII: F446C597KA) (TRIAMCIN | OLONE | | | 1 mg in 1 g | |
| Ingredient Name Strength POLYSORBATE 60 (UNII: CAL22UVI4M) ALUMINUM HYDROXIDE (UNII: SOB0T2IUN0) TITANIUM DIOXIDE (UNII: SOB0T2IUN0) TITANIUM DIOXIDE (UNII: SOB0T2IUN0) TITANIUM DIOXIDE (UNII: SOB0T2IUN0) SORBIC ACID (UNII: SOBTOUNE SOOUPXE4) SORBIC ACID (UNII: SOA5W9898) PROPYLENE GLYCOL (UNII: 6DC9Q167V3) PETROLATUM (UNII: 4T6H12BN9U) METHYLPRABEN (UNII: 28/X2SC10H) SORBIT OL (UNII: 28/X2SC10H) SorBIT OL (UNII: 28/X2SC10H) SorBIT OL (UNII: 28/X2SC10H) Sore Size Product Characteristics Sore Size Imprint Code Ool yellow (light yellow to buff color) Score Size Imprint Code Ool yellow (light yellow to buff color) Score Size Imprint Code Ool yellow (light yellow to buff color) Size Date | Inactive Ingred | ients | | | | | | |
| POLYSORBATE 60 (UNII: CAL22UVI4M) Image: Calabor (UNII: SQB072(UN0) ALUMINUM HYDROXIDE (UNII: SQB072(UN0) Image: Calabor (UNII: SQB072(UN0)) TITANIUM DIOXIDE (UNII: SQF8072(P)) Image: Calabor (UNII: SQB072(P)) GLYCERYL MONOSTEARATE (UNII: 230009XE4) Image: Calabor (UNII: SQB072(P)) SORBIC ACID (UNII: SQF6072(3)) Image: Calabor (UNII: SQF672(3)) PETROLATUM (UNII: 476H12BN9U) Image: Calabor (UNII: S28C2C10H) SORBITOL (UNII: S06T60A25R) Image: Calabor (UNII: S06T60A25R) Product Characteristics Size Color yellow (light yellow to buff color) Size Shape Size Imprint Code Flavor Imprint Code Marketing End 2 Job gi | | | Ingredient Name | | | | Strength | |
| ALUMINUM HYDROXIDE (UNII: 5080721UN0) TITANIUM DIOXIDE (UNII: 15FiX9V2JP) GLYCERYL MONOSTEARATE (UMII: 230009XXE4) SORBIC ACID (UNII: 36FiX9V2JP) PROPYLENE GLYCOL (UMII: 60C9067V3) PETROLATUM (UMII: 476H128N9U) METHYLPARABEN (UMII: 28X2SC10H) SORBITOL (UMII: 506760A25R) PROPYLPARABEN (UMII: 28X2SC10H) SORBITOL (UMII: 506760A25R) Product Characteristics Flavor Product Plavor Product Plave Prod | POLYSORRATE 60 (| | - | | | | Stiength | |
| TITANIUM DIOXIDE (UNII: 15FIX9V2)P) GLYCERYL MONOSTEARATE (UNII: 2300U9XXE4) SORBIC ACID (UNII: K045W989B) PROPYLENE GLYCOL (UNII: 6DC9Q167V3) PETROLATUM (UNII: 476H12BN9U) METHYLPARABEN (UNII: 4218C7H19T) PROPYLPARABEN (UNII: 281X2SC10H) SORBITOL (UNII: 506T60A25R) Product Characteristics Color yellow (light yellow to buff color) Shape 5ize 1000 Flavor 055 Shape 5ize 1000 Packaging 1000 Tem Code 1000 Packaging 1000 Marketing Start 0000 Marketing Start 00000 Marketing Start 00000 Marketing Start 00000 Marketing Start 000000 Marketing Start 0000000 Marketing Start 00000000000000000000000000000000000 | | | | | | | | |
| GLYCERYL MONOSTEARATE (UNII: 2300U9XXE4) Image: State S | | | | | | | | |
| SORBIC ACID (UNII: SO45W9898) PROPYLENE GLYCOL (UNII: 6DC9Q167V3) Image: Sore Sore Sore Sore Sore Sore Sore Sore | | | | | | | | |
| PROPYLENE GLYCOL (UNII: 6DC9Q167V3) PETROLATUM (UNII: 4T6H12BN9U) METHYLPARABEN (UNII: 28IX2SC10H) PROPYLPARABEN (UNII: 28IX2SC10H) SORBITOL (UNII: 500T60A25R) Product Characteristics Color yellow (light yellow to buff color) Score Size Flavor Shape Size Flavor Size Flavor Size Imprint Code Size Flavor Size Size Size Flavor Size Size Size Size Size Size Size Size | | | | | | | | |
| PETROLATUM (UNII: 4T6H12BN9U) Image: State S | | | D167V3) | | | | | |
| Marketing Solution Solution Product Characteristics Size Color yellow (light yellow to buff color) Size Shape Size Flavor Imprint Code Contains Size | | | | | | | | |
| SORBITOL (UNII: 506T60A25R) Product Characteristics Color yellow (light yellow to buff color) Shape Size Flavor Contains Packaging # teen Code Package Description NDC:68071- 30 g in 1 TUBE; Type 0: Not a Combination Product Marketing Start Date | METHYLPARABEN (U | INII: A2I8C7HI | 9T) | | | | | |
| Product Characteristics Score Size Size Imprint Code Packaging # tem Code Package Description Marketing Start Date Marketing End Date 1 NDC:68071- 5037-3 30 g in 1 TUBE; Type 0: Not a Combination Product 08/21/2019 08/21/2019 | PROPYLPARABEN (UI | NII: Z8IX2SC1 | .OH) | | | | | |
| Color yellow (light yellow to buff color) Score Import Size Size Imprint Code Imprint Code Flavor Imprint Code Imprint Code Imprint Code V V V V V NDC:68071- 5037-3 30 g in 1 TUBE; Type 0: Not a Combination Product 08/21/2019 Marketing Start Date Marketing End Date Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date | SORBITOL (UNII: 506 | T60A25R) | | | | | | |
| Color yellow (light yellow to buff color) Score Import Size Size Imprint Code Imprint Code Flavor Imprint Code Imprint Code Imprint Code V V V V V NDC:68071- 5037-3 30 g in 1 TUBE; Type 0: Not a Combination Product 08/21/2019 Marketing Start Date Marketing End Date Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date | | | | | | | | |
| Shape Size Size Flavor Imprint Code Contains Imprint Code Packaging Item Code Package Description # Item Code Package Description Marketing Start Date 1 NDC:68071- 5037-3 30 g in 1 TUBE; Type 0: Not a Combination Product 08/21/2019 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date | Product Charac | teristics | | | | | | |
| Flavor Imprint Code r Item Code Package Description Marketing Start Date Marketing Start Date Marketing Start Date | Color | yellow (light y | ellow to buff color) | | Sco | ore | | |
| Image: Contains Package Description Marketing Start Date Marketing Start NDC: 68071- 5037-3 30 g in 1 TUBE; Type 0: Not a Combination Product 08/21/2019 Marketing Start Marketing Start Marketing Category Application Number or Monograph Marketing Start Date | Shape | | | | Siz | е | | |
| Image: Contains Package Description Marketing Start Date Marketing Start Marketing Start Date Marketing Start NDC:68071- 5037-3 30 g in 1 TUBE; Type 0: Not a Combination Product 08/21/2019 Marketing Information Marketing Start Category Application Number or Monograph Citation Marketing Start Date | Flavor | | | | Imp | orint Cod | le | |
| # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:68071- 5037-3 30 g in 1 TUBE; Type 0: Not a Combination Product 08/21/2019 08/21/2019 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date | Contains | | | | | | | |
| # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:68071- 5037-3 30 g in 1 TUBE; Type 0: Not a Combination Product 08/21/2019 08/21/2019 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date | | | | | | | | |
| # Item Code Package Description Date Date 1 NDC:68071- 5037-3 30 g in 1 TUBE; Type 0: Not a Combination Product 08/21/2019 08/21/2019 Marketing Information Application Number or Monograph Citation Marketing Start Date Marketing Start Date Marketing Encoded | Packaging | | | | | | | |
| Sold Sold Sold Sold Sold Sold Sold Sold | # Item Code | Pac | kage Description | Ν | | | Marketing End Date | |
| Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date | | | E; Type 0: Not a Combinatio | on 08/2 | 21/2019 | | | |
| Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date | | | | | | | | |
| Category Citation Date Date | Marketing Information | | | | | | | |
| | | Applicat | | raph | | - | Marketing End Date | |
| ANDA ANDA062364 12/22/1987 | | | 4 | | 12/22/1007 | | | |

| Establishment | | | | | | | | | |
|------------------------------|---------|-----------|----------------------------|--|--|--|--|--|--|
| Name | Address | ID/FEI | Business Operations | | | | | | |
| NuCare Pharmaceuticals, Inc. | | 010632300 | relabel(68071-5037) | | | | | | |

Revised: 2/2021

NuCare Pharmaceuticals, Inc.